Santiola süstelahus Eesti - eesti - Ravimiamet

santiola süstelahus

krka d.d. novo mesto - klosanteel - süstelahus - 50mg 1ml 250ml 4tk; 50mg 1ml 250ml 1tk

DOLMEN õhukese polümeerikattega tablett Eesti - eesti - Ravimiamet

dolmen õhukese polümeerikattega tablett

menarini international operations luxembourg s.a. - deksketoprofeen - õhukese polümeerikattega tablett - 12,5mg 40tk; 12,5mg 20tk; 12,5mg 500tk; 12,5mg 10tk

LOSARTAN STADA õhukese polümeerikattega tablett Eesti - eesti - Ravimiamet

losartan stada õhukese polümeerikattega tablett

stada arzneimittel ag - losartaan - õhukese polümeerikattega tablett - 12,5mg 100tk; 12,5mg 98tk; 12,5mg 30tk; 12,5mg 28tk; 12,5mg 21tk

DOLMEN suukaudse lahuse graanulid Eesti - eesti - Ravimiamet

dolmen suukaudse lahuse graanulid

menarini international operations luxembourg s.a. - deksketoprofeen - suukaudse lahuse graanulid - 12,5mg 100kott; 12,5mg 50kott; 12,5mg 30kott; 12,5mg 20kott; 12,5mg 10kott; 12,5mg 2kott

LOSARTAN/HYDROCHLOROTHIAZIDE STADA õhukese polümeerikattega tablett Eesti - eesti - Ravimiamet

losartan/hydrochlorothiazide stada õhukese polümeerikattega tablett

stada arzneimittel ag - losartaan+hüdroklorotiasiid - õhukese polümeerikattega tablett - 100mg+12,5mg 98tk

LOSARTAN/HYDROCHLOROTHIAZIDE STADA õhukese polümeerikattega tablett Eesti - eesti - Ravimiamet

losartan/hydrochlorothiazide stada õhukese polümeerikattega tablett

stada arzneimittel ag - losartaan+hüdroklorotiasiid - õhukese polümeerikattega tablett - 50mg+12,5mg 56tk; 50mg+12,5mg 30tk

Oyavas Euroopa Liit - eesti - EMA (European Medicines Agency)

oyavas

stada arzneimittel ag - bevatsizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastilised ained - oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. lisateavet inimese epidermaalse kasvufaktori retseptori 2 (her2) seisundi kohta vt palun 5. jaotisest. oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with oyavas in combination with capecitabine. her2 staatuse kohta lisateabe saamiseks lugege palun 5. jaotist. oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

PRENOXAD süstelahus süstlis Eesti - eesti - Ravimiamet

prenoxad süstelahus süstlis

ethypharm - naloksoon - süstelahus süstlis - 0,91mg 1ml 2ml 1tk

Zypadhera Euroopa Liit - eesti - EMA (European Medicines Agency)

zypadhera

eli lilly nederland b.v. - olanzapine pamoaat - skisofreenia - psühhoeptikumid - säilitusraviks täiskasvanud patsientidel skisofreenia suukaudse akuutse suukaudse ravi ajal.

ANAMIBA õhukese polümeerikattega tablett Eesti - eesti - Ravimiamet

anamiba õhukese polümeerikattega tablett

stada arzneimittel ag - estsitalopraam - õhukese polümeerikattega tablett - 20mg 200tk; 20mg 100tk; 20mg 98tk; 20mg 56tk; 20mg 20tk; 20mg 50tk; 20mg 30tk; 20mg 10tk; 20mg 14tk; 20mg 28tk